ESR1 and breast cancer: Indeed, the development of estrogen receptor (ER) and progesterone receptor (PR)-positive breast cancer (24–28) markedly occurs in post-menopausal women, while the incidence of ER-negative tumors is more frequent in pre-menopausal patients (9).